2026 Appendix 4E and Annual Report
Filed with ASX · · 88 pages · English
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Mayne Pharma reports unaudited Q4 and FY26 results
- Mayne Pharma receives $14.4m for legal costs from Cosette
- Court awards MYX $13.27m for legal costs from Cosette
- Mayne Pharma reports unaudited 3Q FY26 results
- S&P DJI Announces March 2026 Quarterly Rebalance
Later from Mayne Pharma
- 2026 Full Year Results Media Release
- MYX settles US patent litigation re Imvexxy with Sun Pharma
- Trading Halt
- Supreme Court Decision in Cosette Proceedings
- MYX settles US patent litigation re Imvexxy with Teva USA
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma